Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Commerce Bank

Commerce Bank lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.1% in the third quarter, Holdings Channel.com reports. The fund owned 11,949 shares of the medical equipment provider’s stock after selling 260 shares during the quarter. Commerce Bank’s holdings in Hologic were worth $973,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HOLX. Cetera Investment Advisers lifted its holdings in shares of Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares in the last quarter. Andra AP fonden lifted its holdings in shares of Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after purchasing an additional 66,000 shares in the last quarter. Swedbank AB lifted its holdings in shares of Hologic by 5.2% in the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock valued at $121,060,000 after purchasing an additional 80,575 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 582 shares in the last quarter. Finally, Comerica Bank lifted its holdings in shares of Hologic by 40.9% in the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after purchasing an additional 31,967 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HOLX shares. Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Raymond James increased their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada increased their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Trading Up 0.3 %

Hologic stock opened at $78.97 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market capitalization of $18.34 billion, a price-to-earnings ratio of 23.71, a PEG ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The company’s fifty day moving average price is $80.44 and its two-hundred day moving average price is $78.35.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.89 earnings per share. On average, analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.